Metagenomi Therapeutics (MGX) Change in Taxes (2023)

Metagenomi Therapeutics (MGX) reported Change in Taxes of $1.1 million for Q4 2023, up 301.1% quarter-over-quarter from -$546000.0 in Q3 2023.

Metagenomi Therapeutics (MGX) Change in Taxes (2023) Analysis & Trends

Metagenomi Therapeutics (MGX) has 1 years of Change in Taxes data on file, last reported at $1.1 million in Q4 2023.

Change in Taxes for Q4 2023 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $552000.0 (down 68.09% YoY), and the FY2024 annual result was -$3.3 million, down 288.79% from the prior year.
Change in Taxes grew to $1.1 million in Q4 2023 per MGX's latest filing, from -$546000.0 in the prior quarter.
Over five years, Change in Taxes peaked at $1.9 million in Q1 2023 and troughed at -$759000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Taxes (Qtr)
1	Alterity Therapeutics	821,726.73 Bn	821,726.69 Bn	-	-
2	Belite Bio	57,768.00 Bn	57,768.00 Bn	-	-
3	Quantum Biopharma	16,655.88 Bn	16,655.88 Bn	-	-
4	Legend Biotech	3,540.00 Bn	3,539.71 Bn	242.10 Mn	-
5	Evaxion A	1,526.26 Bn	1,526.24 Bn	-	-
6	Akari Therapeutics	1,520.09 Bn	1,520.09 Bn	-	-
7	Psyence Biomedical	223.87 Bn	223.87 Bn	-	-
8	Vertex Pharmaceuticals	114.47 Bn	107.23 Bn	2.59 Bn	-
9	Abivax	91.22 Bn	91.22 Bn	-	-
10	Metagenomi Therapeutics	42.84 Mn	42.84 Mn	-	-

Download Data